Intervention Review

You have free access to this content

Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C

  1. Goran Hauser1,2,*,
  2. Tahany Awad2,
  3. Kristian Thorlund3,
  4. Davor Štimac1,
  5. Mahasen Mabrouk4,
  6. Christian Gluud2

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 28 FEB 2014

Assessed as up-to-date: 30 MAY 2012

DOI: 10.1002/14651858.CD005642.pub3


How to Cite

Hauser G, Awad T, Thorlund K, Štimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C. Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD005642. DOI: 10.1002/14651858.CD005642.pub3.

Author Information

  1. 1

    Clinical Hospital Centre Rijeka, Department of Gastroenterology, Rijeka, Croatia

  2. 2

    Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital, The Cochrane Hepato-Biliary Group, Copenhagen, Denmark

  3. 3

    McMaster University, Department of Clinical Epidemiology and Biostatistics, Hamilton, Ontario, Canada

  4. 4

    Faculty of Medicine, Cairo University, Endemic Medicine and Liver Department, Cairo, Egypt

*Goran Hauser, ghauser@medri.hr.

Publication History

  1. Publication Status: New
  2. Published Online: 28 FEB 2014

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Ascione 2010 {published data only}
  • Ascione A, De Luca M, Tartaglione MT, Lampasi F, Lanza AG, Picciotto FP, et al. Peginterferon alfa-2a plus ribavirin Is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010;138(1):116-22.
  • Ascione A, De Luca M, Tartaglione MT, Lampasi F, Lanza AG, Picciotto FP, et al. Peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. Hepatology 2008;48(S2):370.
Berak 2005 {published data only}
  • Berak H, Horban A, Wasilewski M, Stanczak JJ, Kolakowska-Rzadzka A. Randomized, open label trial comparing efficacy and safety of pegylated interferon alfa 2A vs alfa 2B treatment of patients with chronic hepatitis C infected with non 2/3 genotypes-12 week virological response analysis. Hepatology 2005;42(4 S1):684A.
Bruno 2004 {published data only}
  • Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antiviral Therapy 2004;9(4):491-7.
  • Bruno R, Sacchi P, Maiocchi L, Zocchetti C, Ciappina V, Patruno S, et al. Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C. Antiviral Therapy 2005;10(2):201-5.
  • Bruno R, Sacchi P, Scagnolari C, Torriani F, Maiocchi L, Patruno S, et al. Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study. Alimentary Pharmacology & Therapeutics 2007;26(3):369-76.
Di Bisceglie 2007 {published data only}
  • Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. Viral Hepatitis 2007;14(10):721-9.
  • Di Bisceglie AM, Rustgi VK, Thuluvath P, Davis M, Ghalib R, Lyons MF, et al. Pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2A or alfa-2B with ribavirin in treatment naive patients with genotype 1 chronic hepatitis C. Hepatology 2004;40(S4):734A.
Kamal 2011 {published data only}
Kolakowska 2008 {published data only}
  • Kolakowska A, Berok H, Wasilewski M, Horbon A. Relevance between fibrosis and response to treatment with peginterferon alfa2a vs alfa2b with ribavirin in chronic hepatitis C genotype 3 patients. Randomized open label study. Hepatology 2008;48(4):1278.
Laguno 2009 {published data only}
Mach 2011 {published data only}
  • Mach TH, Cieśla A, Warunek W, Janas-Skulina U, Cibor D, Owczarek D. Efficacy of pegylated interferon alfa-2aor alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b. Polskie Archiwum Medycyny Wewnetrznej 2011;121:434-40.
Marcellin 2011 {published data only}
McHutchison 2009 {published data only}
  • McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine 2009;361(6):580-93.
Miyase 2012 {published data only (unpublished sought but not used)}
  • Miyase S, Haraoka K, Ouchida Y, Morishita Y, Fujiyama S. Randomized trial of peginterferon a-2a plus ribavirin versus peginterferon a-2b plus ribavirin for chronic hepatitis C in Japanese patients. Journal of Gastroenterology 2012;47(9):1014-21.
  • Miyase S, Morishita Y, Haraoka K, Ouchida Y, Fujiyama S. PEGIFNalpha-2A plus ribavirin shows higher SVR rate compare with PEGIFNalpha-2B plus ribavirin in elderly patients with chronic hepatitis C specially in IL-28B major allele. Journal of Hepatology 2012;56(Suppl 2):S451.
Rumi 2010 {published data only}
  • Rumi M, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Russo R, et al. Randomized study comparing peginterferon-alfa2a plus ribavirin and peginterferon-alfa2b plus ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study. Hepatology 2008;48(4):A212.
  • Rumi M, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Russo R, et al. Randomized study of peginterferon-∝2a plus ribavirin vs peginterferon-∝2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010;138(1):108-15.
Scotto 2008 {published data only}
  • Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di Tullio R, Saracino A, et al. Early and sustained virological response in non-responders with chronic hepatitis C; a randomized open-label study of pegylated interferon-α-2a versus pegylated interferon-α-2b. Drugs 2008;68(6):791-801.
  • Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di Tullio R, Saracino A, et al. Peg-interferon alpha-2a versus peg-interferon alpha-2b in non responders with HCV active chronic hepatitis: A pilot study. Interferon and Cytokine Research 2008;28:623–30.
Silva 2006 {published data only}
  • Silva M, Poo J, Wagner F, Jackson M, Cutler D, Grace M, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). Hepatology 2006;45(2):204-13.
  • Silva M, Poo-Ramirez JL, Wagner F, Jackson M, Laughlin M. Compare trial: Updated data. Hepatology 2008;49(2):288-9.
  • Silva M, Poo-Ramirez JL, Wagner F, Jackson M, Laughlin M. Comparison of peginterferon-alpha2a and peginterferon-alpha2B pharmacokinetics and pharmacodynamic in compare, a randomized, prospective, blinded trial. Hepatology 2004;40(4 S1):192A.
Sinha 2004 {published data only}
  • Sinha S, Gulur P, Patel V, Hage-Nassar G, Tenner S. A randomized prospective clinical trial comparing pegylated interferon alpha 2a/ribavirin versus pegylated interferon alpha 2b/ribavirin in the treatment of chronic hepatitis C. American Journal of Gastroenterology 2004;99(10):237.
Sporea 2006 {published data only}
  • Sporea I, Danila M, Sirli R, Popescu A, Laza A, Baditoiu L. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis. Journal of Gastrointestinal and Liver Diseases 2006; Vol. 15, issue 2:125-30.
Yenice 2006 {published data only}
  • Yenice N, Mehtap O, Gumrah M, Arican N. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turkish Journal of Gastroenterology 2006;17(2):94-8.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Andrade 2006 {published data only}
  • Andrade RJ, González FJ, Vázquez L, Cilvetti A, Camargo R, García-Cortés M, et al. Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels. Antiviral Therapy 2006;11(4):491-8.
Barros 2010a {published data only}
  • Barros FMR, Cheinquer H, Borges LG, Santos E. Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with genotypes 2/3 chronic hepatitis C under the public payer perspective in Brazil. Value in Health 2010;13(3):A71-A72.
Barros 2010b {published data only}
  • Barros FMR, Cheinquer H, Borges LG, Santos E. Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with genotype 1 chronic hepatitis C under the public payer perspective in Brazil. Value in Health 2010;13(3):A72.
Bruchfeld 2006 {published data only}
Cozzolongo 2006 {published data only}
  • Cozzolongo R, Sartorie M, Lanzilotta E, Tonello N, Manghisi OG. Comparison between the two peginterferon's a in the treatment of chronic hepatitis C. Journal of Hepatology 2006;44(S2):209.
Craxi 2008 {published data only}
El Raziky 2013 {published data only}
  • El Raziky M, Fathalah WF, El-Akel WA, Salama A, Esmat G, Mabrouk M, et al. The effect of peginterferon alpha-2a vs. peginterferon alpha-2b in treatment of naive chronic HCV genotype-4 patients: A single centre Egyptian study. Hepatitis Monthly 2013;13:e100694.
Escudero 2008 {published data only}
Espinosa 2007 {published data only}
  • Espinosa M, Arenas MD, Aumente MD, Barril G, Buades JM, Aviles B, et al. Anemia associated with pegylated interferon-alpha 2a and alpha 2b therapy in haemodialysis patients. Clinical Nephrology 2007;67:366-73.
Hofmann 2006 {published data only}
  • Hofmann WP, Bock H, Weber C, Tacke W, Pfaff R, Kihn R, et al. Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists. Zeitschrift für Gastroenterologie 2006;44(1):25-31.
Lee 2010 {published data only}
  • Lee S, Kim IH, Kim SH, Kim SW, Lee SO, Lee ST. Efficacy and tolerability of pegylated interferon-alpha 2a plus ribavirin versus pegylated interferon- alpha 2b plus ribavirin in treatment-naive chronic hepatitis C patients. Intervirology 2010;53:146-53.
Rumi 2012 {published data only}
Villa 2012 {published data only}
Witthoeft 2008 {published data only}
  • Witthoeft T, Hueppe D, John C, Goelz J, Meyer U, Heyne R, et al. Efficacy and safety of peginterferon alfa-2a or -2b plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Germany: The practice study. Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. Hepatology 2008;48(S2):315.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Adeel 2009
Alavian 2010
  • Alavian SM, Behnava B, Tabatabaei SV. The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis. Hepatitis Monthly 2010;10:121-31.
Als-Nielsen 2003
  • Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: A reflection of treatment effect or adverse events?. JAMA 2003;290(7):921-8.
Bailon 2001
  • Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung W-J, Porter JE, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis. Bioconjugate Chemistry 2001;12(2):195-202.
Bangalore 2008
Barros 2010c
  • Barros FMR, Cheinquer H, Borges LG, Santos E. Is there any difference between the effects of therapy with peginterferon-alpha-2a versus standard-dose peginterferon-alpha-2b? A meta-analysis comparing both treatments plus ribavirin in genotype 1/4 chronic hepatitis C virus (HCV) infection patients. Value in Health 2010;13:A368.
Benvegnu 2001
Brok 2005
  • Brok J, Gluud LL, Gluud C. Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD005445]
Brok 2008
  • Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61(8):763-9.
Brok 2009
  • Brok J, Thorlund K, Gluud C, Wetterslev J. Apparently conclusive meta-analyses may be inconclusive - Trial sequential analysis adjustment for random error risk in conclusive Cochrane neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98. [DOI: 10.1093/ije/dyn188]
Chan 2013
  • Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158:200-7.
Cheinquer 2010
  • Cheinquer H, Barros FMR, Borges LG, Santos E, Buschinelli CT. Systematic review and meta-analysis of published randomised controlled trials comparing the efficacy of peginterferon-alpha-2a versus peginterferon alpha-2b both plus ribavirin in chronic hepatitis C patients. Value in Health 2010;13:A69.
Coppola 2011
  • Coppola N, Pisaturo M, Sagnelli C, Tonziello G, Sagnelli E, Angelillo IF. Efficacy and tolerability of peginterferon α-2a and α-2b in patients with chronic hepatitis C by genotype 1: A meta-analysis. Digestive and Liver Diseases 2011;43(Suppl):S94.
CTU 2011
  • Copenhagen Trial Unit. TSA - Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 27 May 2013).
Davis 1999
  • Davis GL. Hepatitis C virus genotypes and quasi species. American Journal of Medicine 1999;107(6B):21S-6S.
DeMets 1987
DerSimonian 1986
Di Biscceglie 2011
Druyits 2012
  • Druyts E, Mills EJ, Nachega J, O’Regan C, Cooper CL. Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. Clinical and Experimental Gastroenterology 2012;5:11-21.
EASL 2012
  • European Association for the Study of the Liver. European Association for the Study of the Liver, EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology 2011;55(2):245-64.
Egger 1997
  • Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
Fattovich 2002
  • Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E, European Concerted Action on Viral Hepatitis (EUROHEP). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. American Journal of Gastroenterology 2002;97(11):288-95.
    Direct Link:
Fernandez- Rodriguez 2010
  • Fernández-Rodríguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rincón D. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. American Journal of Gastroenterology 2010;105:2164-72.
Flori 2013
  • Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, et al. Pegylated interferon-a2a and ribavirin versus pegylated interferon-a2b and ribavirin in chronic hepatitis C. A meta-analysis. Drugs 2013;73:263-77.
Foster 2004
Fried 2002
  • Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Human Services 2002;347:975–82.
Ghany 2009
Ghany 2011
Glue 2000
  • Glue P, Fang JWS, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-alpha 2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clinical Pharmacology and Therapeutics 2000;68(5):556-67.
Gluud 2007
Gluud 2013
  • Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 12. Art. No.: LIVER.
Gurusamy 2014
  • Gurusamy KS, Wilson E, Koretz RL, Allen VB, Davidson BR, Burroughs AK, et al. Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?. PLoS ONE 2014;8(12):e83313.
Guyatt 2008
  • Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.) 2008;336(7650):924-6.
Hadziyannis 2004
  • Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Annals of Internal Medicine 2004;140:346–55.
Higgins 2002
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hirofumi 2009
Hodgson 2003
  • Hodgson HJF. Viral hepatitis - clinical aspects. In: Warrell DA, Cox TM, Firth JD, Benz EJ Jr editor(s). Oxford Textbook of Medicine. 4th Edition. Oxford/ New York: Oxford University Press, 2003.
Hollis 1999
  • Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ (Clinical Research Ed.) 1999;319:670-4.
Hopewell 2009
ICH-GCP 1997
  • International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
Ioannidis 2005
Ioannidis 2005a
Kjaergard 2001
  • Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
Koretz 2013
Lacchetti 2002
  • Lacchetti C, Guyatt G. Therapy and validity: surprising results of randomized controlled trials. In: Guyatt G, Rennie D editor(s). Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. Chicago: AMA Press, 2002:247-65.
Lau 1995
Lee 2008
Lexchin 2003
Lundh 2012
Manns 2001
  • Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-65.
Moher 1998
  • Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
Moher 2012
  • Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. International Journal of Surgery 2012;10:28-55.
Morgan 2010
Myers 2002
  • Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, et al. Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD000370]
OPTN 2008
  • United Network for Organ Sharing. Chapter VI ; Liver and Intestine Transplantation in the United States, 1998-2007. optn.transplant.hrsa.gov/ar2008/chapter_iv_AR_cd.htm?cp=5 (accessed 27 May 2013).
Pasut 2011
Penin 2004
Rambaldi 2008
  • Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Glucocorticosteroids for alcoholic hepatitis – a Cochrane Hepato-Biliary Group Systematic Review with meta-analyses and trial sequential analyses of randomised clinical trials. Alimentary Pharmacology & Therapeutics 2008;27(12):1167-78.
Reddy 2001
RevMan 2012
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Romero-Gomez 2012
  • Romero-Gomez M, Planas R, Sola R, Garcıa-Samaniego J, Diago M, Crespo J, et al. Peginterferon alpha-2A achieves higher early virological responses (RVR and CEVR) than peginterferon alpha-2B in chronic Hepatitis C: Meta-analysis of randomized clinical trials (RCT). Journal of Hepatology 2012;56:S456.
Rosenberg 2001
Royle 2003
  • Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
Rücker 2008
Savovic 2012
  • Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157:429-38.
Savovic 2012a
  • Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
Schulz 1995
  • Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
Seef 2009
Seeff 2002
Singal 2011
  • Singal AK, Jampana SC, Anand BS. Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Digestive Diseases and Sciences 2011;56:2221-26.
Thorlund 2009
Thorlund 2010
  • Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66.
Thorlund 2011
  • Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 23 April 2013):1-115.
Trikalinos 2004
  • Trikalinos TA, Churchill R, Ferri M, Leucht S, Tuunainen A, Wahlbeck K, et al. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. Journal of Clinical Epidemiology 2004;57(11):1124-30.
van Regenmorte 2000
  • van Regenmortel MHV, Fauquet CM, Bishop DHL, Carstens EB, Estes MK, Lemon SM, et al. Virus Taxonomy: The Classification and Nomenclature of Viruses. The Seventh Report of the International Committee on Taxonomy of Viruses. San Diego: Academic Press, 2000:599-621.
Wetterslev 2008
  • Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
Wetterslev 2009
WHO 1999
  • World Health Organization. Global surveillance and control of hepatitis C. Journal of Viral Hepatitis 1999;6(1):35-47.
WHO 2009
  • WHO. International Clinical Trials Registry Platform (ICTRP). www.who.int/ictrp/en/ (accessed 27 May 2013).
Wood 2008
  • Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.
Yang 2013
  • Yang Z, Zhuang L, Yang L, Chen X. Efficacy and tolerability of peginterferon A-2a and peginterferon A-2b, both plus ribavirin, for chronic hepatitis C: A meta-analysis of randomized controlled trials. Gastroenterology Research and Practice 2013;2013:739029.
Zhao 2010
  • Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, et al. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomised trials. Clinical Therapeutics 2010;32:1565-77.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Awad 2009
  • Awad T, Thorlund K, Hauser G, Mabrouk M, Stimac D, Gluud C. Pegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis C. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD005642.pub2]
Awad 2010